Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Key result
Linagliptin did not affect the incidence of hospitalization for heart failure compared to placebo (6.0% vs 6.5%; HR 0.90; 95% CI 0.74-1.08) in patients with type 2 diabetes at high risk.
Why the study?
Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased heart failure risk in individuals with type 2 diabetes mellitus.
Does linagliptin reduce hospitalization for heart failure in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk?
Population
Patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease across 27 countries
Comparison
Linagliptin 5 mg once daily vs placebo
Design
Randomized, placebo-controlled cardiovascular outcomes trial secondary analysis
Follow-up
Median 2.2 years
Authors
Discussion
Loading...
Member takes
Implication
Linagliptin is neutral for heart failure hospitalization; confirms cardiovascular safety without HF benefit in high-risk type 2 diabetes.
Study Design
Type
RCT (n=6,979)
Randomization
1:1
Multicenter
Yes
Structured PICO
Does linagliptin reduce hospitalization for heart failure in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk?
P
Population
6,979 participants (37.1% female) with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease, followed for a median of 2.2 years.
I
Intervention
Linagliptin 5 mg oral once daily on top of standard of care
C
Comparator
Placebo on top of standard of care
O
Outcome
Hospitalization for HF (hHF)hard clinical
Main Result
Hazard Ratio: 0.9 (95% CI 0.74–1.08)
Absolute Event Rate: 6% vs 6.5%
Linagliptin does not increase or decrease the risk of heart failure hospitalization in patients with type 2 diabetes at high cardiovascular and renal risk.
Cite This Study
McGuire et al. (2019) conducted an RCT in Type 2 diabetes mellitus with atherosclerotic cardiovascular disease and/or kidney disease (n=6,979). Linagliptin vs. Placebo was evaluated on Hospitalization for heart failure (hHF) (HR 0.90, 95% CI 0.74-1.08). Linagliptin did not affect the incidence of hospitalization for heart failure compared to placebo (6.0% vs 6.5%; HR 0.90; 95% CI 0.74-1.08) in patients with type 2 diabetes at high risk.